VenomAid Diagnostics

Copenhagen, Denmark· Est. 2019

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VenomAid Diagnostics is a private, pre-revenue biotech/medtech company tackling snakebite envenoming, a neglected tropical disease causing over 100,000 deaths annually. The company is developing a lateral flow assay platform for rapid, multiplex detection of snake venom in biological samples like blood and urine at the point of care. Founded by researchers from the Technical University of Denmark, the company aims to decentralize snakebite care by providing simple, affordable diagnostics to improve clinical outcomes in low-resource settings. Its work is supported by partnerships with research institutions and global health organizations.

Neglected Tropical DiseasesSnakebite Envenoming

Technology Platform

Multiplex lateral flow assay (LFA) platform utilizing monoclonal antibodies for rapid, point-of-care detection and differentiation of snake venoms in biological samples (e.g., blood, urine).

Opportunities

The massive, underserved global burden of snakebite creates a clear need for point-of-care diagnostics.

WHO recognition and philanthropic funding focus present a tailwind for innovation in this space.

The platform technology could potentially be expanded to diagnose envenoming from other venomous animals.

Risk Factors

Developing a robust, manufacturable, and clinically validated test for use in diverse, low-resource settings is a significant technical and regulatory challenge.

Creating a sustainable commercial model and achieving widespread adoption in fragmented public health systems presents major commercialization risks.

Competitive Landscape

The point-of-care snake venom diagnostic market is virtually non-existent, positioning VenomAid as a pioneer. Competition is indirect, stemming from the status quo of clinical syndromic diagnosis or complex lab tests. Academic groups may be developing similar concepts, but few have progressed to a product-focused company stage.